OLE study - Open Label Extension study phase Clarinet with lanreotide Autogel 120 mg in metastatic enteropancreatic neuroendocrine tumors

Abstract

Update the safety and efficacy of anticancer treatment lanreotide AUTOGEL 120 mg in patients with metastatic neuroendocrine tumors enteropankreatických results of the extension study CLARINET.

Keywords

• OLE study
• AUTOGEL
• enteropancreatic neuroendocrine tumors
• metastasis